Effect of rabeprazole versus famotidine on platelet inhibition in patients with normal clopidogrel responsiveness

Trial Profile

Effect of rabeprazole versus famotidine on platelet inhibition in patients with normal clopidogrel responsiveness

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Rabeprazole (Primary) ; Famotidine
  • Indications Cardiovascular disorders; Gastrointestinal disorders
  • Focus Pharmacodynamics
  • Acronyms ACCEL-PROTECT
  • Most Recent Events

    • 17 Oct 2013 New trial record
    • 03 Sep 2013 Primary endpoint 'Platelet-aggregation' has not been met.
    • 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top